Tony Reola
Family · Pittsburgh, PANPI 1144848680
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 561 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 19.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $3,124 and has fallen 64.5% since, to $1,109 in 2025. Among family clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 561 payments — averaging $17.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Gilead$2K
- Viiv Healthcare Company$1K
- Novo Nordisk$515
- Amgen$512
- Lilly USA, LLC$475
- plus $4K from 34 others
What the payments were for
- Travel & lodging$90%
- Food & beverage$9,776100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 108 | $1,880 |
| Gilead | 52 | $1,671 |
| Viiv Healthcare Company | 44 | $1,178 |
| Novo Nordisk | 54 | $515 |
| Amgen | 38 | $512 |
| Lilly USA, LLC | 29 | $475 |
| Pfizer | 28 | $403 |
| Boehringer Ingelheim | 29 | $400 |
| GSK | 17 | $277 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $271 |
| Bayer | 21 | $261 |
| Merck | 16 | $238 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 17 | $204 |
| Biohaven Pharmaceuticals, Inc. | 16 | $195 |
| Currax Pharmaceuticals LLC | 10 | $148 |
| Sanofi-aventis U.S. LLC | 9 | $143 |
| Antares Pharma, Inc. | 6 | $119 |
| Axsome Therapeutics, Inc. | 1 | $103 |
| Johnson & Johnson | 3 | $99 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $77 |
| E.r. Squibb & Sons, L.L.C. | 5 | $74 |
| AstraZeneca | 5 | $67 |
| Amarin Pharma, Inc. | 4 | $66 |
| Eisai Inc. | 3 | $47 |
| Halozyme Inc | 2 | $43 |
| Otsuka America Pharmaceutical, Inc. | 2 | $37 |
| Esperion Therapeutics, Inc. | 2 | $35 |
| Amneal Pharmaceuticals LLC | 2 | $31 |
| Radius Health, Inc. | 2 | $29 |
| Alkermes, Inc. | 1 | $24 |
| Biogen | 1 | $18 |
| Nestle Healthcare Nutrition Inc. | 1 | $18 |
| Indivior Inc. | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Lundbeck LLC | 1 | $16 |
| Organon | 1 | $16 |
| Medtronic | 1 | $16 |
| Hologic Sales And Service, LLC | 1 | $16 |
| Almatica Pharma LLC | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,785 in reported general payments places this provider in the 95th percentile of 4,717 family providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| DescovyEmtricitabine/Tenofov Alafenam | 27 | $53,479 |
| Bupropion XlBupropion Hcl | 12 | $128 |
| Doxycycline Hyclate | 11 | $94 |
| Lisinopril | 14 | $27 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadDescovy | $1,671 | $53,47927 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,717 family providers in Pennsylvania.
Other family in Pittsburgh
- Kathleen ScholzPittsburgh$397K
- Kweilynn GreenePittsburgh$139K
- Margaret RosenzweigPittsburgh$89K
- Patricia HabdasPittsburgh$83K
- Morgan ColePittsburgh$41K
- Amber GrinnellPittsburgh$33K
- Matthew BarnesPittsburgh$25K
- Alexander TatangeloPittsburgh$20K
- Sydney MurrayPittsburgh$19K
- Renee ConnPittsburgh$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.